Navigation Links
KemPharm's KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
Date:8/26/2013

uarter of 2014.  As the safety, tolerability and PK performance of KP201 is further established, we believe the prodrug has the potential to fulfill a significant therapeutic and market need as a first-in-class opioid-based prodrug that possesses the ability to reduce abuse potential and opioid-induced constipation."

About KemPharm

KemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the second quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at www.kempharm.com

For KemPharm, Inc:   

Media / Investor Contacts:

Christal Mickle

319-665-2575

info@kempharm.com

 

 

Jason Rando / Joshua Drumm, Ph.D.

Tiberend Strategic Advisors, Inc.

212.827.0020

jrando@tiberend.com


SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
2. KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
3. Inovio Pharmaceuticals Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
4. Sectra Demonstrates Radiation Dose Monitoring System at AHRA and AAPM Meetings
5. New Data From Partners Center For Connected Health Demonstrates Wireless Mobile Technology Improves Patient Engagement, Outcomes
6. New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR
7. Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
8. Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study
9. New Cardiac Electrical Biomarker Featured In Johns Hopkins Abstract Demonstrates Strong Correlation To High Sensitivity Troponin To Rule Out Acute Myocardial Ischemic Injury
10. MolecularHealth demonstrates Personalized Cancer Therapy Solutions at 2013 CeBIT
11. West Health Institute demonstrates research advances in medical device interoperability to lower the cost of health care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... CUPERTINO, Calif. , March 30, 2015 /PRNewswire/ ... announced that it has initiated a multi-dose Phase ... DUR-928, the lead molecule in DURECT,s Epigenomic Regulator ... entity (NCE) that may have broad applicability in ... (NAFLD) and nonalcoholic steatohepatitis (NASH).  It may also ...
(Date:3/30/2015)... Sorrento Therapeutics, Inc. (Nasdaq: SRNE ) ... to the position of Executive Vice President & ... be responsible for all legal, compliance and intellectual property ... BioDelivery Sciences International, Inc., where he was Senior Vice ... management that led that company to over a six ...
(Date:3/30/2015)... -- Eli Lilly and Company (NYSE: LLY ) ... the investment community and media on the company,s diabetes ... 75th American Diabetes Association® Scientific Sessions, will include multiple ... review of the Phase III data for basal insulin ... The meeting will be held from 7-8:30 ...
Breaking Medicine Technology:DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 3DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 4Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 2Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 3Lilly Announces Date for Diabetes Investor Meeting 2
... ABBOTT PARK, Ill., Feb. 8 A new diagnostic ... form of ovarian cancer may soon be available in the ... simple blood test to help in monitoring for the recurrence or ... be the first automated HE4 test available in the United ...
... HAYWARD, Calif. , Feb. 8 Anthera ... treat serious diseases associated with inflammation, announced today that it ... (FDA) on a Special Protocol Assessment (SPA) for the Phase ... Acute Coronary Syndrome - 16 Weeks) for its lead product ...
Cached Medicine Technology:Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval 2Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval 3Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors 2Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors 3
(Date:3/30/2015)... Los Angeles, CA (PRWEB) March 30, 2015 ... “6 New Ways to Blast Away Fat,” details six new ... these treatments require injections and one is a topical product. ... ( UltraShape and Liposonix ) or freezing cold ... “There are so many options now available to us to ...
(Date:3/30/2015)... 30, 2015 In a recent report ... Governor Chris Christie is championing effective drug and alcohol ... is scrambling to recover funds to stabilize the addiction ... for victims of drug and alcohol addiction. Harbor Village ... plagued by substance use disorders in New Jersey, in ...
(Date:3/30/2015)... This report studies the global pharmacovigilance and drug ... 2014 to 2019. This market is expected to ... to 2019. , Further Inquiry @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=16831714 ... and drug safety software market has been classified ... namely, adverse event reporting software, drug safety audits ...
(Date:3/30/2015)... 2015 Dr. Daniel Shapiro, one of the ... recently featured on Phoenix’s Channel 12 News about the benefits ... minimally invasive alternative to facelifts developed by Dr. Shapiro. , ... at Shapiro Aesthetic Plastic Surgery and Skin Klinic worked closely ... news story on GenXLift. The story detailed the experience and ...
(Date:3/30/2015)... GenSight ®, provider of an Enterprise Portfolio Management ... Forrester Wave™: Strategic Planning For The [Business Technology] BT ... GenSight as a leader and gave the company the ... analytics, corporate strategy, assessment, direction and life cycle support ... Leaders category. , According to the report: GenSight ...
Breaking Medicine News(10 mins):Health News:UltraShape and CoolSculpting: Two New Fat-Busting Technologies 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:Dr. Daniel Shapiro Unveils New Minimally Invasive Facelift Procedure on Local Newscast 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 3
... never make it big in Hollywood as she feels she is too ... short impedes her. She says: I don't think that's ever going to ... tend to look really small on camera. ,'I can probably ... to be it. I have a feeling I am way too small.' ...
... workers who were abducted by Taliban at gunpoint were ... that they were all health workers. // They abduction ... militants snatched on Thursday a vehicle carrying the 15 ... after their identity was made clear, Outlook newspaper quoted ...
... like angioplasty are the various treatments for people ... is a small industrial city in northeast Ohio. ... the country, would suggest their patients to go ... balloon catheters through arteries and sometimes placing drug-coated ...
... Nepal have irked student organizations who came out on the ... roads and stoned vehicles and burnt tyres on the streets. ... population of Nepal is furious with the price hike, which ... student wings of two of the leading parties in the ...
... reports of moderate iodine deficiency among New Zealanders and ... the Trans-Tasman regulator// Food Standards Australia New Zealand (FSANZ) ... iodized salt in some common household products. Recent ... not getting enough of iodine. ,The proposal by ...
... Scientists have achieved a very important milestone in the mapping ... enhance the health and aid better disease// control in cattle. ... industry immensely. ,Scientists firmed up on a sequence ... the value of the difference even in one pair, which ...
Cached Medicine News:Health News:Heart Procedure numbers go haywire in an Ohio City 2Health News:Fuel Price Hike Triggers Violent Protests In Nepal 2Health News:Fuel Price Hike Triggers Violent Protests In Nepal 3
... is a fully adjustable, air-displacement pipette with ... the latest member of the Pipetman family, ... accuracy, and precision. We also added a ... our customers. Eight models cover the full ...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
... Seven digital models cover the range from 2ul ... fluently. Volume lock design prevents inadvertent volume ... horizontal grip. Whole pipette is autoclavable at ... is all polypropylene. Suitable for one-handed operation. ...
This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 0.5-10 microliter range....
Medicine Products: